Posted Thu, Sep, 26,2013
Published today in Clinical Medicine Insights: Therapeutics is a new review article by Stephen K. Field. Read more about this paper below:
Title
Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)
Abstract
Globally, the incidence of tuberculosis (TB) is declining but the proportion of drug-resistant cases has increased. Strains resistant to both isoniazid and rifampin, and possibly other antibiotics, called multidrug-resistant (MDR), are particularly difficult to treat. Poorer outcomes, including increased mortality, occur in patients infected with MDR strains and the costs associated with treatment of MDR-TB are substantially greater. The recent recognition of MDR-TB and strains with more complex resistance patterns has stimulated the development of new TB medications including fluoroquinolones, oxazolidinones, diarylquinolines, nitroimidazopyrans, ethylenediamines, and benzothiazinones. Bedaquiline, a diarylquinoline, was approved for the treatment of MDR-TB in 2012. Addition of delamanid to WHO-approved treatment improved outcomes for MDR-TB and for extensively drug-resistant TB in a large randomized, controlled phase II clinical trial and is undergoing evaluation in a large international phase III study. This review will focus on MDR-TB and the role of delamanid in its treatment.
Click here to learn more about the article, download it and comment
Posted in: Articles Published
News Categories
Thu 08 Oct, 2015
Published This Week (5th - 9th October)Thu 08 Oct, 2015
Biomarker Insights Paper Endorsed by Editor in ChiefWed 07 Oct, 2015
Interview with Professor Jamie DaviesI was delighted with the speed and efficiency with which my paper was processed. The friendly and personal communications with editorial staff also made the experience extremely pleasant and easy. I should be happy to recommend International Journal of Tryptophan Research to anyone.
Facebook Google+ Twitter
Pinterest Tumblr YouTube